Scholarlink

Background <p>This study evaluated the disease phenotype and treatment of axial psoriatic arthritis among patients from Japan compared with those from different geographic regions.</p> Methods <p>Data from the ASAS-PerSpA study were analyzed. Patients with psoriatic arthritis (PsA) with axial involvement, according to a rheumatologist´s judgment, were included. Patients were further categorized by four geographic regions: Europe/North America, Latin America, Middle East/North Africa, and Asia, split into Japan and other Asian countries. Disease and patient characteristics, disease activity, function, and treatment were compared by region.</p> Results <p>Of the 4,465 patients with SpA, 1,033 (23%) were diagnosed with PsA by their rheumatologist. Among those with PsA, 367 (35.5%) had axial involvement (axPsA). Disease activity and function ranges were 4.1–5.4 for BASDAI, 2.5–3.2 for ASDAS, and 3.0–4.7 for BASFI, by regions. In Japan, disease activity and function were relatively lower, indicated by a mean BASDAI of 3.5 (SD 2.4), ASDAS of 2.2 (SD 1.0), and BASFI of 1.6 (SD 2.3). These indexes were also significantly lower than those in other Asian countries, with scores of 4.8 (SD 3.0), 2.2 (SD 2.4), and 3.2 (SD 1.5) respectively. All regions showed variations in the use of csDMARDs and bDMARDs, the utilization rate of csDMARDs was significantly lower in Japan than in other Asian countries (51.4% vs. 78.1%, <i>p</i> = 0.02).</p> Conclusion <p>Patients with axPsA in Japan showed relatively lower disease activity and function than those from different geographic regions, especially in other Asian countries with less frequent csDMARD use.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Disease phenotype and management of axial psoriatic arthritis in Japan compared with other regions, particularly other Asian countries: results of the ASAS-PerSpA study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月3日

查看全文
  • Haruki Sawada,
  • Mitsumasa Kishimoto,
  • Kurisu Tada,
  • Gautam A. Deshpande,
  • Daiki Kobayashi,
  • Masato Okada,
  • Diego Benavent,
  • Chamaida Plasencia-Rodriguez,
  • Victoria Navarro-Compán,
  • Clementina López-Medina,
  • Anna Molto,
  • Maxime Dougados,
  • Naoto Tamura

摘要

Background

This study evaluated the disease phenotype and treatment of axial psoriatic arthritis among patients from Japan compared with those from different geographic regions.

Methods

Data from the ASAS-PerSpA study were analyzed. Patients with psoriatic arthritis (PsA) with axial involvement, according to a rheumatologist´s judgment, were included. Patients were further categorized by four geographic regions: Europe/North America, Latin America, Middle East/North Africa, and Asia, split into Japan and other Asian countries. Disease and patient characteristics, disease activity, function, and treatment were compared by region.

Results

Of the 4,465 patients with SpA, 1,033 (23%) were diagnosed with PsA by their rheumatologist. Among those with PsA, 367 (35.5%) had axial involvement (axPsA). Disease activity and function ranges were 4.1–5.4 for BASDAI, 2.5–3.2 for ASDAS, and 3.0–4.7 for BASFI, by regions. In Japan, disease activity and function were relatively lower, indicated by a mean BASDAI of 3.5 (SD 2.4), ASDAS of 2.2 (SD 1.0), and BASFI of 1.6 (SD 2.3). These indexes were also significantly lower than those in other Asian countries, with scores of 4.8 (SD 3.0), 2.2 (SD 2.4), and 3.2 (SD 1.5) respectively. All regions showed variations in the use of csDMARDs and bDMARDs, the utilization rate of csDMARDs was significantly lower in Japan than in other Asian countries (51.4% vs. 78.1%, p = 0.02).

Conclusion

Patients with axPsA in Japan showed relatively lower disease activity and function than those from different geographic regions, especially in other Asian countries with less frequent csDMARD use.